October 12th 2021
John Kirkwood, MD, PhD, discusses the use of immunotherapy as a treatment option for melanoma, including ctDNA, and how to properly monitor responses.
September 7th 2021
Connie Batlevi, MD, PhD, explains the treatment options for relapsed/refractory follicular lymphoma and discusses a recent drug approval.
July 6th 2021
Javier L. Munoz, MD, MS, FACP, explains the treatment options for relapsed/refractory follicular lymphoma and provides insight into a recent clinical trial.
June 28th 2021
Recommendations for utilizing genomic testing to aid in treatment decisions for early-stage HR+ breast cancer based on updates to the NCCN guidelines.
May 12th 2021
Sameh Gaballa, MD, reviews the treatment options for relapsed/refractory follicular lymphoma and future treatment options.
May 10th 2021
Considerations for adding immunotherapy to the armamentarium for frontline treatment of extensive-stage small cell lung cancer.
May 7th 2021
The current role of genomic testing in HR+ breast cancer and guidance on the use of genomic assays to individualize therapy in the extended adjuvant setting.
March 26th 2021
Experts focus in on optimizing the use of minimal residual disease as a tool to guide decision making in the adjuvant setting for patients at risk for recurrence with colorectal cancer.
January 21st 2021
CancerNetwork spoke with Kenneth C. Anderson, MD, about treatment advances in myeloma - from smoldering, newly diagnosed, and relapsed/refractory multiple myeloma.